High-dose oral glutamine supplementation reduces elevated glutamate levels in cerebrospinal fluid in patients with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome.
María Paz Guerrero-MolinaMontserrat Morales-ConejoAitor DelmiroMaría MoránCristina Domínguez-GonzálezElena Arranz-CanalesAna Ramos-GonzálezJoaquín ArenasMiguel Angel MartinJesús González de la AlejaPublished in: European journal of neurology (2022)
ClinicalTrials.gov Identifier: NCT04948138. Initial release 24 June 2021, first patient enrolled 1 July 2021. https://clinicaltrials.gov/ct2/show/NCT04948138.